Theratechnologies gets FDA nod for new treatment of abdominal fat in HIV patients, shares soar

Theratechnologies

26/03/2025 09:46

** U.S.-listed shares of Canadian drugmaker Theratechnologies TH.TO, THTX.O soar 52.6% to $2.35 premarket

** US FDA has approved THTX's supplemental marketing application for Egrifta WR, a new tesamorelin formulation, to treat excess abdominal fat in HIV patients with a rare condition called lipodystrophy, co said on Tuesday

** Lipodystrophy affects the redistribution of fat that includes the accumulation and loss of fat in certain parts of the human body

** Egrifta WR is a daily injectable medication that only needs to be reconstituted weekly

** Egrifta WR will replace the existing formulation, Egrifta SV, and will be available as a single-patient-use vial, co said

** THTX gained ~15.8% in the last 12 months

 (Reporting by Kamal Choudhury in Bengaluru)

 ((Kamal.Choudhury@thomsonreuters.com;))